Diana Crivellari
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
Jun 1, 2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Jun 1, 2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.
Feb 27, 2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Feb 27, 2010Breast Cancer Res Treat 2010; 123:303-10
Paridaens Robert J, Coates Alan S, Crivellari Diana, Holmberg Stig B, Price Karen N, Thürlimann Beat, Gelber Richard D, Cole Bernard F, Gelber Shari, Goldhirsch Aron
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.
Aug 1, 2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Aug 1, 2009Breast Cancer Res Treat 2009; 116:491-500
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Forbes John F, Murray Elizabeth, Fey Martin F, Thürlimann Beat, Lindtner Jurij, Collins John, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Castiglione-Gertsch Monica, Simoncini Edda, Gelber Shari, International Breast Cancer Study Group
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113:137-44.
Jan 1, 2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Jan 1, 2009Breast Cancer Res Treat 2009; 113:137-44
Thürlimann Beat, Coates Alan S, Castiglione-Gertsch Monica, Forbes John F, Collins John, Colleoni Marco, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Goldhirsch Aron
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Crivellari D, Chirgwin J, Smith I, Rabaglio M, Gladieff L, Del Mastro L, Láng I, Colleoni M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Price K, Coates A, Sun Z, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. JCO 2008; 26:1972-9.
Apr 20, 2008Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Apr 20, 2008JCO 2008; 26:1972-9
Crivellari Diana, Chirgwin Jacquie H, Smith Ian E, Rabaglio Manuela, Gladieff Laurence, Del Mastro Lucia, Láng István, Colleoni Marco, Gelber Richard D, Castiglione-Gertsch Monica, Paridaens Robert J, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Price Karen N, Coates Alan S, Sun Zhuoxin, Goldhirsch Aron
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
May 20, 2007The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
May 20, 2007JCO 2007; 25:2019-26
Karlsson Per, Goldhirsch Aron, Gelber Richard D, Forbes John F, Crivellari Diana, Thürlimann Beat, Fey Martin F, Holmberg Stig B, Collins John P, Lindtner Jurij, Murray Elizabeth, Gusterson Barry A, Castiglione-Gertsch Monica, Coates Alan S, Price Karen N, Cole Bernard F, Wallgren Arne
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
Gruber G, Goldhirsch A, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Carbone A, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, International Breast Cancer Study Group. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. JCO 2005; 23:7089-97.
Oct 1, 2005Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
Oct 1, 2005JCO 2005; 23:7089-97
Gruber Günther, Goldhirsch Aron, Coates Alan S, Gelber Richard D, Fey Martin F, Simoncini Edda, Thürlimann Beat, Carbone Antonino, Crivellari Diana, Collins John, Golouh Rastko, Lindtner Jurij, Holmberg Stig B, Rudenstam Carl-Magnus, Castiglione-Gertsch Monica, Price Karen N, Nasi M Laura, Bonetti Marco, International Breast Cancer Study Group
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Colleoni M, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates A, Price K, Fey M, Collins J, Zahrieh D, Gelber R, Holmberg S, Mattsson J, Rudenstam C, Lindtner J, Erzen D, Snyder R, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. JCO 2005; 23:1390-400.
Mar 1, 2005Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Mar 1, 2005JCO 2005; 23:1390-400
Colleoni Marco, Thürlimann Beat, Crivellari Diana, Murray Elizabeth, Mendiola Caesar, Pagani Olivia, Castiglione-Gertsch Monica, Coates Alan S, Price Karen, Fey Martin F, Collins John, Zahrieh David, Gelber Richard D, Holmberg Stig B, Mattsson Jan E, Rudenstam Carl-Magnus, Lindtner Jurij, Erzen Darja, Snyder Raymond, Goldhirsch Aron